206 related articles for article (PubMed ID: 29664606)
1. Radiometal-Dependent Biological Profile of the Radiolabeled Gastrin-Releasing Peptide Receptor Antagonist SB3 in Cancer Theranostics: Metabolic and Biodistribution Patterns Defined by Neprilysin.
Lymperis E; Kaloudi A; Sallegger W; Bakker IL; Krenning EP; de Jong M; Maina T; Nock BA
Bioconjug Chem; 2018 May; 29(5):1774-1784. PubMed ID: 29664606
[TBL] [Abstract][Full Text] [Related]
2. Theranostic Perspectives in Prostate Cancer with the Gastrin-Releasing Peptide Receptor Antagonist NeoBOMB1: Preclinical and First Clinical Results.
Nock BA; Kaloudi A; Lymperis E; Giarika A; Kulkarni HR; Klette I; Singh A; Krenning EP; de Jong M; Maina T; Baum RP
J Nucl Med; 2017 Jan; 58(1):75-80. PubMed ID: 27493272
[TBL] [Abstract][Full Text] [Related]
3. Preclinical and first clinical experience with the gastrin-releasing peptide receptor-antagonist [⁶⁸Ga]SB3 and PET/CT.
Maina T; Bergsma H; Kulkarni HR; Mueller D; Charalambidis D; Krenning EP; Nock BA; de Jong M; Baum RP
Eur J Nucl Med Mol Imaging; 2016 May; 43(5):964-973. PubMed ID: 26631238
[TBL] [Abstract][Full Text] [Related]
4. Comparing Gly
Lymperis E; Kaloudi A; Kanellopoulos P; de Jong M; Krenning EP; Nock BA; Maina T
Molecules; 2019 Mar; 24(6):. PubMed ID: 30871262
[No Abstract] [Full Text] [Related]
5. Preclinical comparison of Al18F- and 68Ga-labeled gastrin-releasing peptide receptor antagonists for PET imaging of prostate cancer.
Chatalic KL; Franssen GM; van Weerden WM; McBride WJ; Laverman P; de Blois E; Hajjaj B; Brunel L; Goldenberg DM; Fehrentz JA; Martinez J; Boerman OC; de Jong M
J Nucl Med; 2014 Dec; 55(12):2050-6. PubMed ID: 25413139
[TBL] [Abstract][Full Text] [Related]
6. Biological evaluation of (177)Lu-labeled DOTA-Ala(SO3H)-Aminooctanoyl-Gln-Trp-Ala-Val-N methyl Gly-His-Statine-Leu-NH2 for gastrin-releasing peptide receptor-positive prostate tumor targeting.
Lim JC; Cho EH; Kim JJ; Choi SM; Lee Sy; Nam SS; Park UJ; Park SH
Nucl Med Biol; 2015 Feb; 42(2):131-6. PubMed ID: 25457455
[TBL] [Abstract][Full Text] [Related]
7. In Vivo Stabilization of a Gastrin-Releasing Peptide Receptor Antagonist Enhances PET Imaging and Radionuclide Therapy of Prostate Cancer in Preclinical Studies.
Chatalic KL; Konijnenberg M; Nonnekens J; de Blois E; Hoeben S; de Ridder C; Brunel L; Fehrentz JA; Martinez J; van Gent DC; Nock BA; Maina T; van Weerden WM; de Jong M
Theranostics; 2016; 6(1):104-17. PubMed ID: 26722377
[TBL] [Abstract][Full Text] [Related]
8. Amide-to-triazole switch vs. in vivo NEP-inhibition approaches to promote radiopeptide targeting of GRPR-positive tumors.
Maina T; Kaloudi A; Valverde IE; Mindt TL; Nock BA
Nucl Med Biol; 2017 Sep; 52():57-62. PubMed ID: 28636973
[TBL] [Abstract][Full Text] [Related]
9. Comparison of biological properties of [
Rousseau E; Lau J; Zhang Z; Zhang C; Kwon D; Uribe CF; Kuo HT; Zeisler J; Bratanovic I; Lin KS; Bénard F
J Labelled Comp Radiopharm; 2020 Feb; 63(2):56-64. PubMed ID: 31715025
[TBL] [Abstract][Full Text] [Related]
10. Comparative evaluation of the new GRPR-antagonist
Lymperis E; Kaloudi A; Kanellopoulos P; Krenning EP; de Jong M; Maina T; Nock BA
J Labelled Comp Radiopharm; 2019 Aug; 62(10):646-655. PubMed ID: 30963606
[TBL] [Abstract][Full Text] [Related]
11. Evaluation of a 1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid-conjugated bombesin-based radioantagonist for the labeling with single-photon emission computed tomography, positron emission tomography, and therapeutic radionuclides.
Mansi R; Wang X; Forrer F; Kneifel S; Tamma ML; Waser B; Cescato R; Reubi JC; Maecke HR
Clin Cancer Res; 2009 Aug; 15(16):5240-9. PubMed ID: 19671861
[TBL] [Abstract][Full Text] [Related]
12. 68Ga/177Lu-NeoBOMB1, a Novel Radiolabeled GRPR Antagonist for Theranostic Use in Oncology.
Dalm SU; Bakker IL; de Blois E; Doeswijk GN; Konijnenberg MW; Orlandi F; Barbato D; Tedesco M; Maina T; Nock BA; de Jong M
J Nucl Med; 2017 Feb; 58(2):293-299. PubMed ID: 27609789
[TBL] [Abstract][Full Text] [Related]
13. In vivo enzyme inhibition improves the targeting of [177Lu]DOTA-GRP(13-27) in GRPR-positive tumors in mice.
Marsouvanidis PJ; Melis M; de Blois E; Breeman WA; Krenning EP; Maina T; Nock BA; de Jong M
Cancer Biother Radiopharm; 2014 Nov; 29(9):359-67. PubMed ID: 25286347
[TBL] [Abstract][Full Text] [Related]
14. A comparative PET imaging study of
Ferguson S; Wuest M; Richter S; Bergman C; Dufour J; Krys D; Simone J; Jans HS; Riauka T; Wuest F
Nucl Med Biol; 2020; 90-91():74-83. PubMed ID: 33189947
[TBL] [Abstract][Full Text] [Related]
15. In Vivo Stabilized SB3, an Attractive GRPR Antagonist, for Pre- and Intra-Operative Imaging for Prostate Cancer.
Bakker IL; van Tiel ST; Haeck J; Doeswijk GN; de Blois E; Segbers M; Maina T; Nock BA; de Jong M; Dalm SU
Mol Imaging Biol; 2018 Dec; 20(6):973-983. PubMed ID: 29556947
[TBL] [Abstract][Full Text] [Related]
16. Trastuzumab cotreatment improves survival of mice with PC-3 prostate cancer xenografts treated with the GRPR antagonist
Mitran B; Rinne SS; Konijnenberg MW; Maina T; Nock BA; Altai M; Vorobyeva A; Larhed M; Tolmachev V; de Jong M; Rosenström U; Orlova A
Int J Cancer; 2019 Dec; 145(12):3347-3358. PubMed ID: 31077356
[TBL] [Abstract][Full Text] [Related]
17. Preclinical pharmacokinetic, biodistribution, imaging and therapeutic efficacy of (177)Lu-Labeled glycated bombesin analogue for gastrin-releasing peptide receptor-positive prostate tumor targeting.
Lim JC; Cho EH; Kim JJ; Choi SM; Lee SY; Nam SS; Park UJ; Park SH
Nucl Med Biol; 2015 Mar; 42(3):234-41. PubMed ID: 25498002
[TBL] [Abstract][Full Text] [Related]
18. Characterization and evaluation of DOTA-conjugated Bombesin/RGD-antagonists for prostate cancer tumor imaging and therapy.
Stott Reynolds TJ; Schehr R; Liu D; Xu J; Miao Y; Hoffman TJ; Rold TL; Lewis MR; Smith CJ
Nucl Med Biol; 2015 Feb; 42(2):99-108. PubMed ID: 25459113
[TBL] [Abstract][Full Text] [Related]
19. Bombesin antagonist-based radioligands for translational nuclear imaging of gastrin-releasing peptide receptor-positive tumors.
Abiraj K; Mansi R; Tamma ML; Fani M; Forrer F; Nicolas G; Cescato R; Reubi JC; Maecke HR
J Nucl Med; 2011 Dec; 52(12):1970-8. PubMed ID: 22080443
[TBL] [Abstract][Full Text] [Related]
20. Development of Heterobivalent Theranostic Probes Having High Affinity/Selectivity for the GRPR/PSMA.
Bandari RP; Carmack TL; Malhotra A; Watkinson L; Fergason Cantrell EA; Lewis MR; Smith CJ
J Med Chem; 2021 Feb; 64(4):2151-2166. PubMed ID: 33534560
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]